Actavis, Inc. (NYSE: ACT) has launched Montelukast tablets immediately after patent expiry in Denmark, France, Germany, Ireland, Italy, the Netherlands, Slovenia, Spain, Sweden and the UK. In Austria, Actavis started pricing and reimbursement on day 1.
The generic equivalent of Merck’s Singulair®, Montelukast tablets are indicated for the treatment of asthma. Montelukast Actavis is available as regular tablets for ages 15 years and older and chewable tablets for children, 2–5 and 6–15 years old.
For the 12 months ending September 2012, Montelukast 10 mg tablets had branded and generic sales of approximately €458m in Europe, according to IMS Health data, while Montelukast chewable tablets, 4mg and 5mg, sold for about €153m during the same period.
Montelukast tablets are manufactured by Actavis in Malta.